PR Newswire
NEW YORK
,
Feb. 25, 2021
/PRNewswire/ — Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Pandion Therapeutics, Inc.
(NASDAQ: PAND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck for
$60.00
per share in cash.
If you are a Pandion shareholder,
click here to learn more about your rights and options
.
PRA Health Sciences, Inc.
(NASDAQ: PRAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ICON plc. Under the terms of the transaction, PRA Health shareholders will receive
$80.00
in cash and 0.4125 shares of ICON stock for each PRA Health share that they own.
If you are a PRA Health shareholder,
click here to learn more about your rights and options
.
Aegion Corporation
(NASDAQ: AEGN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to affiliates of New Mountain Capital, L.L.C. for
$26.00
per share in cash.
If you are an Aegion shareholder,
click here to learn more about your rights and options
.
Protective Insurance Corporation
(NASDAQ: PTVCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to The Progressive Corporation for
$23.30
in cash for each share of Protective Class A and Class B common stock.
If you are a Protective shareholder,
click here to learn more about your rights and options
.
CRH Medical Corporation
(NYSE: CRHM) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Well Health Technologies Corp. for
$4.00
per share.
If you are a CRH Medical shareholder,
click here to learn more about your rights and options
.
Cleveland BioLabs, Inc.
(NASDAQ: CBLI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Cytocom, Inc. Under the merger, Cleveland BioLabs stockholders are expected to own approximately 39% of the combined company.
If you are a Cleveland BioLabs shareholder,
click here to learn more about your rights and options
.
Akers Biosciences, Inc.
(NASDAQ: AKER) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with MyMD Pharmaceuticals, Inc.
If you are an Akers shareholder,
click here to learn more about your legal rights and options
.
Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm
free of charge
to discuss their legal rights and options. Please call
Daniel Sadeh
or
Zachary Halper
at (212) 763-0060 or email
[email protected]
or
[email protected]
.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
View original content to download multimedia:
http://www.prnewswire.com/news-releases/investigation-alert-halper-sadeh-llp-investigates-the-following-companies-on-behalf-of-shareholders–pand-prah-aegn-ptvca-crhm-cbli-aker-301236207.html
SOURCE Halper Sadeh LLP
